Contact type glasses nursing composition

Abstract

The invention provides a contact type glasses care composition, and relates to the technical field of treating fluid. The raw material components of the contact glasses care composition comprise a first copolymer; the first copolymer is formed by polymerizing polymerizable monomers containing a first functional monomer and a second functional monomer; the first functional monomer is selected from acrylate containing cholagoyl phosphate; the second functional monomer is selected from alkyl acrylate; the polymerizable monomer also comprises a third functional monomer, and the third functional monomer is N-vinyl pyrrolidone; or the raw material component also comprises a homopolymer or a copolymer of N-vinyl pyrrolidone. The care composition provided by the invention synergistically exerts the effects of cholayl phosphate and polyvinyl pyrrolidone, and has a good desorption or removal effect on protein adsorbed on the lens.

Description

Technical Field

[0001] The invention belongs to the technical field of treatment liquids and relates to a contact lens care composition. Background Art

[0002] Wearing corneal contact lenses (such as contact lenses, cosmetic lenses, etc.) has become a daily behavior for many people. The tears secreted by the human eye contain components such as proteins and oils, which are easily adhered to the surface of the corneal contact lens, forming a layer of protein precipitation of uneven thickness and affecting the performance of the lens, such as poor oxygen permeability, shortened life, etc., and will also cause the wearer to have aggravated foreign body sensation, occasional discomfort, and even allergies. In particular, corneal contact lenses with good hydrophilicity are more susceptible to protein adsorption. In the prior art, there are generally two methods for treating this protein precipitation. The first method is to covalently bond and graft a thin layer of anti-protein adhesion material on the surface of the corneal contact lens to reduce the adhesion of proteins, oils, etc.; the second method is to add protein removal components to the daily care solution, and the adhered proteins, oils, etc. will be removed after the corneal contact lens is immersed in the care solution.

[0003] For the above method (2), one way is to add a polymer containing choline phosphate acrylate, which has good resistance to protein adsorption and can improve the desorption and removal effect of proteins adsorbed on the lens surface. The raw materials for manufacturing corneal contact lenses include acrylic acid, methacrylic acid, hydroxyethyl methacrylate, N-vinyl pyrrolidone, N,N-dimethylformamide, butyl acrylate, butyl methacrylate, vinyl acetate, trifluoroethyl methacrylate, hexafluoroisopropyl methacrylate, allyl methacrylate, ethylene glycol dimethacrylate, siloxane styrene, siloxane methacrylate, silicone macromers, etc. Corneal contact lenses can be divided into hard, semi-hard and soft types according to hardness, but due to the raw material composition, they are all prone to protein adsorption during wearing. Especially for corneal contact lenses containing polysiloxane components, polysiloxane has a good adsorption property for protein, resulting in higher requirements for the removal ability of the care solution for the adhered protein.

[0004] Therefore, contact lens care solutions still need further improvement to further enhance the ability to remove adsorbed proteins. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides a contact lens care composition.

[0006] The technical solution of the present invention is as follows:

[0007] A contact lens care composition, the raw material components comprising a first copolymer;

[0008] The first copolymer is formed by polymerizing a polymerizable monomer comprising a first functional monomer and a second functional monomer;

[0009] The first functional monomer is selected from choline-phosphophosphate-containing acrylate;

[0010] The second functional monomer is selected from alkyl acrylates;

[0011] The polymerizable monomer further comprises a third functional monomer, and the third functional monomer is N-vinyl pyrrolidone;

[0012] or,

[0013] The raw material components also contain a homopolymer or copolymer of N-vinyl pyrrolidone.

[0014] Preferably, the weight proportion of the choline phosphoryl-containing acrylate in the polymerizable monomer is not less than 20%.

[0015] Preferably, the structure of the choline phosphoryl-containing acrylate is as shown in the following formula (1):

[0016]

[0017] Among them, R 1 is selected from H or C1-C4 alkyl, R 2 Selected from C1-C10 alkylene, -(CH2CH2O) m -or-(CH2CHCH3O) n -, m=1-10, n=1-10, a=1-10, R 3 , R 4 and R 5 Independently selected from C1-C8 alkyl.

[0018] Preferably, the weight proportion of the alkyl acrylate in the polymerizable monomer is not less than 30%.

[0019] Preferably, the structure of the alkyl acrylate is as shown in the following formula (2):

[0020] CH2=C(R 6 )COOR 7 (2)

[0021] Among them, R 6 is selected from H or C1-C4 alkyl, R 7 Selected from C1-C8 alkyl or C2-C6 hydroxyalkyl.

[0022] Preferably, the weight proportion of the N-vinyl pyrrolidone in the polymerizable monomer is 1-25%.

[0023] Preferably, the weight percentage of the first copolymer in the raw material components is not less than 0.03%.

[0024] Preferably, the number average molecular weight of the homopolymer or copolymer of N-vinyl pyrrolidone is 3,000-50,000.

[0025] Preferably, the weight percentage of N-vinyl pyrrolidone in the copolymer of N-vinyl pyrrolidone is not less than 60%.

[0026] Preferably, the raw material components further include one or a combination of two or more of water, preservatives, humectants, surfactants, sodium chloride, pH buffers, chelating agents and disinfectants.

[0027] The beneficial effect of the present invention is as follows: the present invention finds that a first copolymer containing cholyl phosphate-containing acrylate is added to the care composition, combined with an N-vinyl pyrrolidone polymer segment, the N-vinyl pyrrolidone polymer segment can be combined in the first copolymer in a copolymer manner, or can be physically blended with the first copolymer in the form of a homopolymer or a copolymer. The care composition of the present invention can synergistically exert the anti-protein adsorption performance of the cholyl phosphate-containing acrylate and the N-vinyl pyrrolidone polymer segment, thereby improving the desorption or removal effect of the care composition on proteins adsorbed on the surface of corneal contact lenses. DETAILED DESCRIPTION

[0028] The technical solution of the present invention is further illustrated and described below through specific implementation methods.

[0029] In order to further improve the desorption or removal effect of the care solution on the proteins adsorbed on the corneal contact lens during the wearing process, the present invention provides a contact lens care composition, the raw material components include a first copolymer;

[0030] The first copolymer is formed by polymerizing a polymerizable monomer including a first functional monomer and a second functional monomer;

[0031] The first functional monomer is selected from choline-phosphoryl-containing acrylate;

[0032] The second functional monomer is selected from alkyl acrylates;

[0033] The polymerizable monomer further comprises a third functional monomer, and the third functional monomer is N-vinyl pyrrolidone;

[0034] or,

[0035] The raw material components also contain homopolymers or copolymers of N-vinylpyrrolidone.

[0036] The copolymer containing cholyl phosphate-containing acrylate and the homopolymer or copolymer of polyvinyl pyrrolidone both have good anti-protein adsorption performance and can play a role in desorbing or removing proteins adsorbed on the surface of the lens. The present invention unexpectedly found that the copolymer containing cholyl phosphate-containing acrylate and the homopolymer or copolymer of polyvinyl pyrrolidone, whether a chemically bonded combination or a physically blended combination, can be added to the care composition to better play the desorption or removal performance of proteins adsorbed on the surface of the lens compared to the separate copolymer containing cholyl phosphate-containing acrylate and the homopolymer or copolymer of polyvinyl pyrrolidone.

[0037] In the present invention, the first copolymer can be prepared by solution polymerization, the solvent can be ethanol, tetrahydrofuran, butyl acetate, DMF, DMAc, DMSO, etc., and the free radical initiator can be azobisisobutyronitrile AIBN, azobisisoheptanenitrile ABVN, etc.

[0038] In a preferred embodiment of the present invention, the weight proportion of choline phosphate-containing acrylate in the polymerizable monomer is not less than 30%. The weight proportion of choline phosphate-containing acrylate in the polymerizable monomer is not high enough, and the anti-protein effect is not obvious. For example, the weight proportion of choline phosphate-containing acrylate in the polymerizable monomer can be any value of 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, etc., without special restrictions. More preferably, the weight proportion of choline phosphate-containing acrylate in the polymerizable monomer does not exceed 80%, otherwise the hydrophilicity of the first copolymer is too good, which will cause the care composition to not achieve better desorption or removal performance of proteins adsorbed on the lens surface.

[0039] In a preferred embodiment of the present invention, the structure of the acrylate containing choline phosphate is shown in the following formula (1):

[0040]

[0041] Among them, R 1 is selected from H or C1-C4 alkyl, R 2 Selected from C1-C10 alkylene, -(CH2CH2O) m -or-(CH2CHCH3O) n -, m=1-10, n=1-10, a=1-10, R 3 , R 4 and R 5independently selected from C1-C8 alkyl. For example, the phosphorylcholine-containing (meth)acrylate in the present invention can be (meth)acryloyloxyethyl phosphorylcholine (MPC), (meth)acryloyloxypropyl phosphorylcholine, 4-((meth)acryloyloxy)butyl-2'-(trimethylammonium)ethyl phosphate, 2-[(meth)acryloylamino]ethyl-2'-(trimethylammonium)-ethyl phosphate, 3-[(meth)acryloylamino]propyl-2'-(trimethylammonium)ethyl phosphate, 4-[(meth)acryloylamino]butyl-2'-(trimethylammonium)ethyl phosphate, 5-((meth)acryloyloxy)pentyl-2'-(trimethylammonium)ethyl phosphate, 6-((meth)acryloyloxy)hexyl-2'-(trimethylammonium)ethyl phosphate. -(trimethylammonio)-ethyl phosphate, 2-((meth)acryloyloxy)ethyl-2'-(triethylammonio)ethyl phosphate, 2-((meth)acryloyloxy)ethyl-2'-(tripropylammonio)ethyl phosphate, 2-((meth)acryloyloxy)ethyl-2'-(tributylammonio)ethyl phosphate, 2-((meth)acryloyloxy)propyl-2'-(trimethylammonio)-ethyl phosphate, 2-((meth)acryloyloxy)butyl-2'-(trimethylammonio)ethyl phosphate, 2-((meth)acryloyloxy)pentyl-2'-(trimethylammonio)ethyl phosphate, 2-((meth)acryloyloxy)hexyl-2'-(trimethylammonio)ethyl phosphate, and the like. In the present invention, the phosphorylcholine group-containing (meth)acrylate is a zwitterionic acrylate, and other zwitterionic acrylate monomers may be used instead, such as an acrylate monomer containing a betaine group, for example, sulfobetaine methacrylate, [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfonatepropyl)ammonium hydroxide, carboxybetaine methacrylate, and the like.

[0042] In a preferred embodiment of the present invention, the weight proportion of alkyl acrylate in the polymerizable monomer is not less than 20%. If the weight proportion of alkyl acrylate in the polymerizable monomer is too low, the hydrophilicity of the first copolymer is too good, which will lead to the care composition not being able to achieve better desorption or removal performance of proteins adsorbed on the lens surface. For example, the weight proportion of alkyl acrylate in the polymerizable monomer can be any value of 20%, 25%, 30%, 35%, 40%, 45%, 50%, etc., without special restrictions. More preferably, the weight proportion of alkyl acrylate in the polymerizable monomer is not higher than 50%. If the weight proportion of alkyl acrylate in the polymerizable monomer is too high, the hydrophobicity of the first copolymer will be too good and the hydrophilicity will be too poor, which will lead to the care composition not being able to achieve better desorption or removal performance of proteins adsorbed on the lens surface.

[0043] In a preferred embodiment of the present invention, the structure of the alkyl acrylate is shown in the following formula (2):

[0044] CH2=C(R 6 )COOR 7 (2)

[0045] R 6 is selected from H or C1-C4 alkyl, R 7 Selected from C1-C8 alkyl or C2-C6 hydroxyalkyl.

[0046] For example, the alkyl acrylate of the present invention can be ethyl (meth)acrylate, butyl (meth)acrylate, hydroxyethyl (meth)acrylate, hydroxypropyl (meth)acrylate, etc., among which more preferably, the weight proportion of butyl (meth)acrylate in the alkyl acrylate is not less than 50%, that is, the weight proportion of butyl (meth)acrylate in the alkyl acrylate can be any value of 50%, 60%, 70%, 80%, 90%, 100%, etc., without special restrictions.

[0047] In a preferred embodiment of the present invention, the weight proportion of N-vinyl pyrrolidone in the polymerizable monomer is 1-25%. For example, the weight proportion of N-vinyl pyrrolidone in the polymerizable monomer can be any value of 1%, 2%, 3%, 5%, 8%, 10%, 12%, 15%, 17%, 18%, 20%, 22%, 25%, etc., without special restrictions. Too high or too low weight proportion of N-vinyl pyrrolidone in the polymerizable monomer is not conducive to synergizing with choline phosphate-containing acrylate to desorb or remove adsorbed proteins. More preferably, the weight proportion of N-vinyl pyrrolidone in the polymerizable monomer is 5-25%.

[0048] In a preferred embodiment of the present invention, the weight percentage of the first copolymer in the raw material component is not less than 0.03%. More preferably, the weight percentage of the first copolymer in the raw material component is not higher than 1%. For example, the weight percentage of the first copolymer in the raw material component can be any value in 0.03%, 0.05%, 0.07%, 0.08%, 0.1%, 0.12%, 0.13%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1.0%, etc., without special restrictions.

[0049] In a preferred embodiment of the present invention, the number average molecular weight of the homopolymer or copolymer of N-vinyl pyrrolidone is 3000-50000. More preferably, the number average molecular weight of the homopolymer or copolymer of N-vinyl pyrrolidone is 5000-20000. The weight proportion of the homopolymer or copolymer of N-vinyl pyrrolidone in the raw material components can be 0.005-0.1%. For example, the weight proportion can be any value in 0.005%, 0.01%, 0.012%, 0.015%, 0.017%, 0.018%, 0.02%, 0.025%, 0.03%, 0.035%, 0.04%, 0.045%, 0.05%, 0.055%, 0.06%, 0.065%, 0.07%, 0.075%, 0.08%, 0.085%, 0.09%, 0.1%, etc., without special restrictions. Or, more preferably, the weight proportion of the homopolymer or copolymer of N-vinyl pyrrolidone in the raw material components can be 0.01-0.05%.

[0050] In a preferred embodiment of the present invention, the weight percentage of N-vinyl pyrrolidone in the copolymer of N-vinyl pyrrolidone is not less than 60%. By adopting the above technical scheme, the function of N-vinyl pyrrolidone in desorption or removal of adsorbed proteins can be better exerted, and the effect can be synergistically exerted with the choline phosphate-containing acrylate.

[0051] In a preferred embodiment of the present invention, the raw material components also include one or a combination of two or more of water, preservatives, humectants, surfactants, sodium chloride, pH buffers, chelating agents and disinfectants. For example, the preservative can be parabens, polyquaternium-1, sodium perborate, etc., and the amount used can be 0.01-0.15% by weight of the care composition; the humectant can be propylene glycol, glycerin, hyaluronic acid, polyethylene glycol, etc., and the amount used can be 0.1-0.6% by weight of the care composition; the surfactant can be sodium stearate, sodium laurate, sodium dodecyl sulfate, sodium dodecylbenzene sulfonate, AEO-6, AEO-9, etc., and the amount used can be 0.01-0.3% by weight of the care composition; the pH buffer can be The chelating agents may be EDTA, disodium EDTA-disodium, citric acid, etc., and the dosage may be 0.05-0.5% of the weight of the care composition; the disinfectants may be hydrogen peroxide, boric acid, biguanide, etc., and the dosage may be 0.01-0.5% of the weight of the care composition.

[0052] The preparation method of the contact lens care composition of the present invention can be as follows: directly add the raw material components to water in sequence, and stir until dissolved to obtain the contact lens care composition. For the raw material components that dissolve slowly at room temperature, they can be added to water first, heated to dissolve, and then cooled and the remaining raw material components can be added in sequence to obtain the contact lens care composition.

[0053] The technical solution of the present invention is further described and illustrated according to various embodiments below. Unless otherwise specified, the parts described in the following embodiments are parts by weight.

[0054] Preparation Example 1-6 Preparation of the First Copolymer

[0055] Preparation Example 1

[0056] 70 parts of (meth)acryloyloxyethyl phosphorylcholine, 20 parts of butyl acrylate and 10 parts of N-vinyl pyrrolidone are added to 250 parts of anhydrous ethanol, and 1 part of AIBN is added. The mixture is stirred and heated to 70°C and reacted at a constant temperature for 8 hours. The mixture is cooled to room temperature, and the solution is added to 4000 parts of ether for precipitation. The precipitate is collected by filtration, washed twice with ether, and dried in an oven at 50°C overnight to obtain a first copolymer.

[0057] Preparation Example 2

[0058] The difference between Preparation Example 2 and Preparation Example 1 is that in Preparation Example 1, (meth)acryloyloxyethyl phosphorylcholine is adjusted from 70 parts to 60 parts, and butyl acrylate is adjusted from 20 parts to 30 parts. The remaining steps remain unchanged.

[0059] Preparation Example 3

[0060] The difference between Preparation Example 3 and Preparation Example 1 is that in Preparation Example 1, (meth)acryloyloxyethyl phosphorylcholine is adjusted from 70 parts to 50 parts, and butyl acrylate is adjusted from 20 parts to 40 parts. The remaining steps remain unchanged.

[0061] Preparation Example 4

[0062] The difference between Preparation Example 4 and Preparation Example 2 is that in Preparation Example 2, (meth)acryloyloxyethyl phosphorylcholine is adjusted from 60 parts to 50 parts, and N-vinyl pyrrolidone is adjusted from 10 parts to 20 parts. The remaining steps remain unchanged.

[0063] Preparation Example 5

[0064] The difference between Preparation Example 5 and Preparation Example 1 is that in Preparation Example 1, butyl acrylate is adjusted from 20 parts to 30 parts, and N-vinyl pyrrolidone is adjusted from 10 parts to 0 parts. The other steps remain unchanged.

[0065] Preparation Example 6

[0066] The difference between Preparation Example 6 and Preparation Example 1 is that in Preparation Example 1, (meth)acryloyloxyethyl phosphorylcholine is adjusted from 70 parts to 80 parts, and N-vinyl pyrrolidone is adjusted from 10 parts to 0 parts. The remaining steps remain unchanged.

[0067] Example 1

[0068] The care composition, based on 100% by weight, consists of the following raw material components: 0.15% of the first copolymer of Preparation Example 1, 0.1% of polyquaternium salt-1, 0.5% of glycerol, 0.2% of sodium dodecylbenzene sulfonate, 0.9% of sodium chloride, 0.8% of sodium dihydrogen phosphate, 0.2% of EDTA-disodium and 0.1% of disinfectant water, and the balance is pure water.

[0069] Add each raw material component into pure water in turn, stir until the solution becomes transparent and uniform, and then continue stirring for 5 minutes to obtain the product.

[0070] Example 2

[0071] The difference between this example and Example 1 is that in Example 1, the first copolymer of Preparation Example 1 is replaced by the first copolymer of Preparation Example 2 with the same weight percentage. The other steps remain unchanged.

[0072] Example 3

[0073] The difference between this example and Example 1 is that in Example 1, the first copolymer of Preparation Example 1 is replaced by the first copolymer of Preparation Example 3 with the same weight percentage. The other steps remain unchanged.

[0074] Example 4

[0075] The difference between this example and Example 1 is that in Example 1, the first copolymer of Preparation Example 1 is replaced by the first copolymer of Preparation Example 4 with the same weight percentage. The other steps remain unchanged.

[0076] Example 5

[0077] The difference between this example and Example 1 is that in Example 1, the first copolymer of Preparation Example 1 is replaced by the first copolymer of Preparation Example 5 with the same weight percentage. The other steps remain unchanged.

[0078] Example 6

[0079] The difference between this example and Example 1 is that in Example 1, the first copolymer of Preparation Example 1 is replaced by the first copolymer of Preparation Example 6 with the same weight percentage. The other steps remain unchanged.

[0080] Example 7

[0081] The difference between this embodiment and embodiment 5 is that in embodiment 5, 0.01% homopolymer of N-vinyl pyrrolidone (number average molecular weight 12000) is added, and the weight percentage of pure water is reduced accordingly. The other steps remain unchanged.

[0082] Example 8

[0083] The difference between this embodiment and embodiment 5 is that in embodiment 5, 0.05% of the homopolymer of N-vinyl pyrrolidone in embodiment 7 is added, and the weight percentage of pure water is reduced accordingly. The other steps remain unchanged.

[0084] Commercially available corneal contact lenses (silicone hydrogel contact lenses) were immersed in 3 ml of artificial tears and left to stand at 37°C for 24 hours. The protein weight in the solution was quantified using the BCA method (the calibration curve was bovine serum albumin), and the amount of protein adsorbed by the corneal contact lenses was measured to be 1.80-1.87 mg.

[0085] Artificial tears composition: 1.2 mg / ml lysozyme, 3.88 mg / ml albumin, 1.61 mg / ml γ-globulin, 9.00 mg / ml sodium chloride, 0.14 mg / ml potassium dihydrogen phosphate, 0.80 mg / ml disodium hydrogen phosphate heptahydrate, and the remainder is pure water.

[0086] Three corneal contact lenses after protein adsorption were taken and immersed in 3 ml of the care composition of Examples 1-8 and pure water respectively, and immersed at 25° C. for 12 hours. The lenses were taken out and the weight of protein in each care composition and pure water was tested respectively. The protein removal rate was calculated as the weight of protein in the care composition or pure water / the weight of protein adsorbed on the lens×100%, and the average of the three results was taken. The results are shown in Table 1 below.

[0087] Table 1

[0088]

[0089]

[0090] It can be seen from the data results in Table 1 above that the contact lens care composition of the present invention has a good removal effect on the protein adsorbed on the lens, and whether introducing N-vinyl pyrrolidone polymer chain scissors into the first copolymer or adding N-vinyl pyrrolidone homopolymer separately, the removal effect of the care composition on the protein adsorbed on the lens can be improved.

[0091] Example 9

[0092] The care composition, based on 100% by weight, comprises 0.1% of the first copolymer of Preparation Example 1, 0.12% of polyquaternium-1, 0.3% of glycerol, 0.15% of sodium dodecylbenzene sulfonate, 0.9% of sodium chloride, 0.6% of sodium dihydrogen phosphate, 0.25% of disodium EDTA and 0.12% of disinfectant water, and the remainder is pure water.

[0093] Add each raw material component into pure water in turn, stir until the solution becomes transparent and uniform, and then continue stirring for 5 minutes to obtain the product.

[0094] Example 10

[0095] The difference between this embodiment and embodiment 9 is that in embodiment 9, the first copolymer of preparation example 1 is adjusted from 0.1% to 0.3%, and the content of pure water is reduced accordingly. The other steps remain unchanged.

[0096] Embodiment 11

[0097] The difference between this embodiment and embodiment 9 is that in embodiment 9, the first copolymer of preparation example 1 is adjusted from 0.1% to 0.5%, and the content of pure water is reduced accordingly. The other steps remain unchanged.

[0098] Example 12

[0099] The difference between this embodiment and embodiment 9 is that in embodiment 9, 0.02% of homopolymer of N-vinyl pyrrolidone (number average molecular weight 10000) is added, the weight percentage of pure water is reduced accordingly, and the content of pure water is reduced accordingly. The other steps remain unchanged.

[0100] Embodiment 13

[0101] The difference between this example and Example 12 is that in Example 12, the first copolymer of Preparation Example 1 is replaced by the first copolymer of Preparation Example 5 with the same weight percentage. The other steps remain unchanged.

[0102] Embodiment 14

[0103] The difference between this embodiment and embodiment 13 is that in embodiment 13, the first copolymer of preparation example 5 is adjusted from 0.1% to 0.3%, and the weight percentage of pure water is reduced accordingly. The other steps remain unchanged.

[0104] Embodiment 15

[0105] The difference between this embodiment and embodiment 14 is that in embodiment 14, the homopolymer of N-vinyl pyrrolidone is not added, and the weight percentage of pure water is increased accordingly. The other steps remain unchanged.

[0106] Example 16

[0107] The difference between this embodiment and embodiment 13 is that in embodiment 13, the first copolymer of preparation example 1 is adjusted from 0.1% to 0.3%, and the weight percentage of pure water is reduced accordingly. The other steps remain unchanged.

[0108] The protein removal rates of Examples 9-16 were tested according to the above-mentioned protein removal rate test method. The results are shown in Table 2 below.

[0109] Table 2

[0110]

[0111] From the results in Table 2 above, it can be seen that in the first copolymer of the raw material component of the care composition of the present invention, the phosphorylcholine structural unit can produce a synergistic effect with vinyl polypyrrolidone, so that the care composition can desorb and remove the protein adsorbed on the lens.

[0112] As described above, the basic principles, main features and advantages of the present invention are shown and described. Those skilled in the art should understand that the present invention is not limited by the above embodiments, which are only preferred embodiments of the present invention and cannot be used to limit the scope of the present invention. That is, equivalent changes and modifications made according to the scope of the present invention and the content of the specification should still be within the scope of the present invention. The scope of protection required by the present invention is defined by the attached claims and their equivalents.

Claims

1. A contact lens care composition, characterized in that: The feedstock components include a first copolymer; The first copolymer is formed by polymerizing a polymerizable monomer comprising a first functional monomer and a second functional monomer; The first functional monomer is selected from choline-phosphophosphate-containing acrylate; The second functional monomer is selected from alkyl acrylates; The polymerizable monomer further comprises a third functional monomer, and the third functional monomer is N-vinyl pyrrolidone; or, The raw material components also contain a homopolymer or copolymer of N-vinyl pyrrolidone.

2. The contact lens care composition according to claim 1, characterized in that The weight proportion of the choline phosphoryl-containing acrylate in the polymerizable monomer is not less than 20%.

3. The contact lens care composition according to claim 1, characterized in that The structure of the choline-phosphoryl acrylate is shown in the following formula (1): Among them, R 1 is selected from H or C1-C4 alkyl, R 2 Selected from C1-C10 alkylene, -(CH2CH2O) m -or-(CH2CHCH3O) n -, m=1-10, n=1-10, a=1-10, R 3 , R 4 and R 5 Independently selected from C1-C8 alkyl.

4. The contact lens care composition according to claim 1, characterized in that The weight percentage of the alkyl acrylate in the polymerizable monomer is not less than 30%.

5. The contact lens care composition according to claim 1, characterized in that The structure of the alkyl acrylate is shown in the following formula (2): CH2=C(R 6 )COOR 7 (2) Among them, R 6 is selected from H or C1-C4 alkyl, R 7 Selected from C1-C8 alkyl or C2-C6 hydroxyalkyl.

6. The contact lens care composition according to claim 1, characterized in that The weight proportion of the N-vinyl pyrrolidone in the polymerizable monomer is 1-25%.

7. The contact lens care composition according to claim 1, characterized in that The weight percentage of the first copolymer in the raw material components is not less than 0.03%.

8. The contact lens care composition according to claim 1, characterized in that The number average molecular weight of the homopolymer or copolymer of N-vinyl pyrrolidone is 3,000-50,000.

9. The contact lens care composition according to claim 1, characterized in that The weight percentage of N-vinyl pyrrolidone in the copolymer of N-vinyl pyrrolidone is not less than 60%.

10. The contact lens care composition according to claim 1, characterized in that The raw material components also include one or a combination of two or more of water, preservatives, moisturizers, surfactants, sodium chloride, pH buffers, chelating agents and disinfectants.

Images